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Abstract A number of experimental observations in the late 1960s, early 1970s
could not be explained by the pharmacokinetic theory available at that time. For
example rats receiving phenobarbital as an enzyme inducing agent exhibited
increased elimination of phenylbutazone in vitro in liver microsomes and in vivo in
whole animals compared to that observed in non-induced animals. However, for
desipramine, although phenobarbital increased elimination in microsomes, no
change in plasma disappearance was noted in vivo for this drug between rats
induced with phenobarbital and control rats. Similar in vitro–in vivo discordancies
were seen with changes in protein binding. The introduction of clearance concepts
in the early 1970s by Professor Rowland and others provided the scientific rationale
for these apparently contradictory findings and the recognition that clearance, not
half-life, was the measure of the body’s ability to eliminate drugs and most
importantly that changes in pathology and physiology could be correlated with
measures of clearance. Up to that time half-life was well recognized in terms of
basic chemical principles as an appropriate measure of the rate of elimination and
reflective of changes in the rate of elimination. The difference between chemistry
and pharmacokinetics, however, is that in chemistry the volume in which the
reaction occurs does not change. In contrast, in pharmacokinetics, disease states and
differences in physiology can change the space available in which the drug may
distribute in the body. Thus, it was necessary to develop a pharmacokinetic measure of
volume that was independent of elimination, i.e., Vss. Now, the relationship between
Vss and clearance led to a unique measure of time of drug in the body, the mean
residence time. Although this parameter is calculated in all PK programs, very few
pharmaceutical scientists know how it can be useful. Very recently, we have shown
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that the concepts of accumulation, prediction of which is the clinically relevant use for
half-life and mean residence time, are flawed and that the appropriate time dependent
parameter to predict accumulation has not been previously correctly identified.
Finally, when clearance concepts were developed our understanding of the importance
of drug transporters was nonexistent. A critical, and generally unrecognized
assumption (which is only explicitly stated in Professor Rowland’s seminal 1973
paper), in the development of the theory of clearance is that the unbound drug con-
centration in the organ of elimination is in a constant equilibrium with the unbound
drug concentration in the systemic circulation, where drug concentration measure-
ments are made. Transporter drug–drug and disease interactions may, in fact, change
this equilibrium and potentially what we consider as intrinsic clearance, may not be
independent of an eliminating organ volume parameter, contrary to what we have been
teaching for the past 37 years.
Keywords Clearance  Volume of distribution  Mean residence time  Multiple
dosing half lives
Introduction
I am pleased and honored to participate in this dedicatory issue honoring Professor
Malcolm Rowland’s 70th birthday and his outstanding contributions to the fields of
pharmacokinetics and pharmacodynamics. Reviewing the pharmacokinetic litera-
ture 40 years ago almost all published studies were carried out with salicylic acid.
This was because the drug was given in large doses, and primarily because we had a
colorimetric assay, using the Trinder method, that allowed us to measure plasma and
urinary concentrations. Professor Rowland had 11 such publications between 1966
and 1972 investigating the pharmacokinetics of salicylic acid. However, the
mathematical models that were developed and the equations that accompanied these
models, although of interest to the cognoscente, were incomprehensible to clinicians
treating patients. Furthermore, there appeared to be no useful relationship between
the changes in these pharmacokinetic parameters and the degree of disease, which
would allow translation of pharmacokinetics into patient drug dosing.
Clearance
So, in 1972, what was wrong with pharmacokinetics? It appeared to have no
relationship with clinically meaningful parameters that could help in making drug
dosing decisions or that could account for differences in physiology and pathology.
For example at steady state:
Rate In ¼ Rate Out
Availability  Dosing Rate ¼ ??  Average Concentration
F  Dosing Rate ¼ ??  Target Concentration
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It was well known that at steady state the Rate In would be the dosing rate at which
the drug was administered multiplied by the bioavailability (F), which could change
as a function of the route of administration. It was recognized that Rate Out should
relate to systemic concentrations or to a target concentration that was known to
yield efficacy with minimum toxicity. However, the parameter that was to be
multiplied by this systemic target concentration was undefined in 1972. Therefore,
Professor Rowland and others applied a term from physiology to whole body drug
elimination and called it clearance (CL). So that at steady state:
Rate In ¼ Rate Out
Availability  Dosing Rate ¼ Clearance  Concentration at steady  state
F  Dose=s ¼ CL  Css ð1Þ
A number of experimental observations in the late 1960s, early 1970s could not be
explained by the pharmacokinetic theory available at that time. For example von Bahr
et al. [1] observed that for rats receiving phenobarbital as an enzyme inducing agent
the elimination of phenylbutazone was increased both in vitro in liver microsomes and
in vivo in whole animals versus that observed in non-induced animals. However, for
the drug desipramine, although elimination was increased in microsomes from
phenobarbital induced rats, no change in plasma disappearance was noted in vivo for
this intravenous dosed drug between rats induced with phenobarbital and control rats.
That is, in some cases elimination of the drug was increased in both the microsomes
and in vivo, but in other cases in vitro induction was seen, but no in vivo induction.
Another series of studies related to protein binding also showed discordancies for
certain drugs between in vitro and in vivo studies. Kru¨ger-Thiemer et al. [2] had
investigated the renal elimination of highly protein bound sulfanilamides in healthy
volunteers. They showed in vitro that inhibition of protein binding would increase free
concentrations of these drugs. They reasoned, therefore, that in vivo they would
expect the renal elimination of these sulfanilamides to increase when protein binding
was inhibited. For some of the sulfanilamides this in vivo increase in renal elimination
was observed, however, for a number of sulfanilamides no change in renal elimination
was found when free concentrations of the drugs were increased by inhibiting protein
binding. Thus, it appeared in the early 1970s that pharmacokinetics did not provide
any predictability of changes in elimination based on induction of metabolic enzymes
or through increasing free drug concentrations.
However, the introduction of clearance concepts in pharmacokinetics by
Rowland et al. [3] and the further explication by Wilkinson and Shand [4]
alleviated these problems. Rate of elimination for an individual organ can be defined
as the product of blood flow to that organ (Q) and the difference between the arterial
(CA) and venous (CV) concentrations as shown below:
Rate of elimination ¼ Q  CA  Q  CV
From Eq. 1, organ clearance equals the rate of elimination divided by the con-
centration as shown in Eq. 2, where the difference in arterial and venous concen-
trations divided by the incoming arterial concentration may be defined as the
extraction ratio (ER) of the organ.
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CLorgan ¼ ðQ  CA  Q  CVÞ=CA
¼ Q  ðCA  CVÞ=CA ¼ Q  ER
ð2Þ
However, Eq. 2 would not explain the anomalies listed above with respect to
enzyme induction and protein binding. Thus the development of clearance in
pharmacokinetics [3, 4] was advanced by describing the ER in terms of the ‘‘well-
stirred’’ model that we borrowed from the chemical engineers as used by them in
modeling the ‘‘cracking’’ of petroleum to make gasoline. We define ER as a
function of three parameters:
a. blood flow to the elimination organ
b. the intrinsic ability of the organ to eliminate the unbound drug as if there were
no flow and protein binding limitations
c. the fraction of the drug unbound in the blood.
Rowland et al. [3] introduced parameters a and b in their definition of the organ
clearance of unbound drug. Wilkinson and Shand [4] added the protein binding
parameter to allow conversion for total drug clearance characterization. In terms of
the well stirred model, clearance (with respect to blood concentrations) for the
eliminating organ then becomes:
CLorgan ¼ Q  ðfub  CLintÞ=ðQ þ fub  CLintÞ ð3Þ
where CLint is the intrinsic unbound clearance by the organ and fub is the unbound
fraction of drug in blood. Equation 3 demonstrates that when the capability of the
eliminating organ to metabolize the drug is large in comparison to the rate of drug
presentation to the organ, i.e., (fubCLint)  Q, the clearance will approximate the
organ blood flow
CLorgan ffi Q ð4Þ
That is, drug elimination is limited by blood flow rate and the compound is called a
high-ER drug. On the other hand, when the metabolic capacity is small in comparison
to the rate of drug presentation, i.e., Q  (fubCLint), the clearance will be propor-
tional to the unbound fraction of drug in blood and the intrinsic clearance, as in Eq. 5.
CLorgan ffi fub  CLint ð5Þ
The drug is then called a low-ER drug. When the capability for elimination is of the
same order of magnitude as the blood flow, clearance is dependent upon the blood
flow as well as on the intrinsic clearance and the blood protein binding (Eq. 3).
Note that the definitions for low- and high-ER drugs are independent of the
fraction of the dose eliminated by a particular organ. For example, diazepam is
eliminated almost completely by hepatic metabolism (less than 1% of the drug is
excreted unchanged in the urine), yet the clearance of diazepam, 27 ml/min,
indicates that this is a low hepatic ER drug. That is, on each pass through the liver
only a small fraction of the drug (ERH = CLH/QH = 27/1,500 = 0.018) will be
eliminated, although eventually almost all of the drug will be eliminated by the
liver. The value of 1,500 is the average hepatic blood flow (QH) in ml/min for a
70 kg man in calculating the hepatic ER (ERH).
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Equation 3 clarifies a number of the unresolvable experimental results described
above. For example, following intravenous dosing, enzyme induction or hepatic
disease may change the rate of desipramine metabolism in a hepatic microsomal
enzyme system, but no change in clearance is found in the whole animal with
similar hepatic changes. This is explained by the fact that desipramine is a high-
extraction-ratio drug and clearance becomes limited by blood flow rate (Eq. 4), so
that changes in CLint due to enzyme induction or liver disease have little effect on
clearance. Also, although desipramine is a relatively highly protein bound drug
(fub = 0.18), changes in protein binding due to disease or competitive binding
should have little effect on clearance. In contrast, for a low-extraction-ratio drug
such as phenylbutazone (CL = 1.6 ml/min/70 kg), enzyme induction or changes in
protein binding (fub = 0.039) should markedly affect elimination since Eq. 5
describes this drug’s elimination following intravenous dosing.
A second extremely insightful and influential paper published by Professor
Rowland in Journal of Pharmaceutical Sciences in 1972 was entitled, ‘‘The
Influence of Route of Administration on Drug Availability’’ [5]. This paper contains
the first physiologic based quantitative prediction of first-pass hepatic elimination to
appear in the pharmacokinetic literature.
FH ¼ 1  ERH ¼ 1  CLH=QH ð6Þ
I utilized this equation earlier to calculate the ER of diazepam, but it is more
instructive to utilize Eq. 6 in terms of labetalol. Labetalol is a high-ER drug with a
hepatic blood clearance of 1,290 ml/min in a 70 kg human and a drug with an oral
bioavailability of only 18%. Inserting the labetalol hepatic blood clearance and the
average hepatic blood flow into Eq. 6 gives an ERH = 0.86 Thus, from Eq. 6 the
hepatic bioavailability of labetalol is only 14% with the great majority of the oral
dose being metabolized on its first pass through the liver prior to reaching the
systemic circulation. Thus, it can be seen that the low oral bioavailability of
labetalol is only due to physiology, i.e., giving the drug orally whereby it must first
pass through the liver before reaching the systemic circulation (note: the small
differences between the predicted FH and the actual oral bioavailability are due to
the fact that the numbers here are for average subjects and coefficients of variation
for labetalol clearance and bioavailability are 40 and 30%, respectively). Equation 6
provides very useful information concerning labetalol that although the drug has
poor oral bioavailability, it is not due to dosage form defects, permeability problems
or intestinal metabolism. Rather giving labetalol by the oral route of administration
leads to a significant decrease in hepatic first-pass bioavailability that can only be
overcome by choosing an alternate route of administration.
The introduction [3] of clearance concepts to pharmacokinetics beginning in
1973 has had an immense effect on the field. Reviewing PubMed for the term ‘‘drug
clearance’’ one finds in 1972 that there were 192 references, many of them dealing
with mucociliary drug clearance. In the year 2006 the total number of references
increased to more than 29,000 and as of the time of the oral presentation of this
work (October 5, 2009) the number of references was 47,827. At submission of the
final version for publication (November 4, 2010) the number of references has
increased to 50,199. Thus, beginning in 1973 it was recognized that clearance, not
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half-life, was a measure of the body’s ability to eliminate drug and changes in
pathology or physiology could be correlated with measures of clearance.
Volume of distribution
This initially created some confusion because up to that time half life was well
recognized in terms of basic chemical principles as an appropriate measure of the
rate of elimination and reflective of changes in the rate of elimination. However, the
difference between chemistry and pharmacokinetics is that in chemistry the volume
in which the reaction occurs does not change. In contrast, in pharmacokinetics,
disease states and differences in physiology can change the space available in which
the drug may distribute in the body. Thus, it was necessary to develop a measure of
volume of distribution that was independent of elimination. Such a volume term has
been defined as volume of distribution at steady state (Vss). Although clearance
could be determined independent of the previously employed pharmacokinetic
models by determining the dose divided by the area under the curve (AUC), no
noncompartmental method for determining Vss was available until 1979. Then
Benet and Galeazzi [6] defined a noncompartmental method for determination of
Vss. This paper was the first to describe the relationship between Vss, CL and a
measure of time of drug in the body, the mean residence time (MRT).
Vss ¼ CL  MRT ð7Þ
Now it was recognized that clearance and volume were the independent
parameters and that half life or MRT was the dependent parameter. Changes in
either clearance or volume could change half life. The work of Klotz et al. [7]
studying the effects of age on the disposition of diazepam nicely demonstrates this
point. Terminal plasma half life of diazepam exhibited a striking age dependence
going from about 20 h for 20 year old men and increasing linearly with age to about
90 h at 80 years. The plasma clearance of diazepam showed no significant age
dependence. The change in half life is due to the redistribution of body fluids with
age causing more diazepam to distribute out of the fluids delivered to the liver, the
organ of elimination. Since less drug is available to the liver, drug remains in the
body longer and half life increases, but the elimination process has not been
affected. Another excellent example of clearance and volume not changing in
parallel, so that half life changes don’t reflect clearance changes is the data for
digoxin. Everyone today uses the equations of Sheiner et al. [8] who suggested how
to predict CL and V in patients with varying renal function, either exhibiting or not
exhibiting marked congestive heart failure.
However, there are relatively few well documented cases in the literature of the
clearance and volume discordance, probably because no clinician would make dose
adjustments (mg/day) based on volume of distribution changes. Dose adjustments are
made based on clearance changes as given in Eq. 1. Therefore, very few investigators
calculate the volume changes and when they do, they seldom focus even on
significant changes because they are immaterial in making dose adjustments. There is
now, however, beginning to be a significant literature base where this information is
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available and that relates to drug-drug interactions that are transporter based. This is
because changes in transporter activity would be expected to change drug distribution
characteristic as well as metabolism changes (the latter due to transporter-enzyme
interplay [9]). This is in contrast to enzymatic drug-drug interactions where no change
in volume would be expected. Human studies of inhibition of hepatic OATP
transporter uptake for atorvastatin [10] and particularly glyburide [11] show that
significant changes in volume do not parallel changes in clearance and thus half life
changes would not be useful in predicting dose adjustments. Recognizing that volume
would change in transporter interaction studies, Grover and Benet [12] summarized
the effects of drug transporters on volume of distribution. All of these interaction
studies provide a database to confirm the relationship depicted in Eq. 7 and the lack of
parallel changes of clearance and half life.
Thus in summary from Eq. 7, clearance is a measure of the body’s ability to
eliminate drug. Volume of distribution is a measure of the space available in the
body in which a drug may distribute. Pathology and physiology can change both CL
and Vss thereby changing MRT or half life. So the question then becomes why do
we want to know half life?
Half life
I believe that the only clinically relevant use of half life is to predict accumulation
upon multiple dosing. That is, knowing the therapeutically beneficial drug dosing
rate, based on clearance and bioavailability (Eq. 1), what is the appropriate dosing
interval to maximize efficacy and minimize toxicity? What half life do we use to
make that calculation? I have come to realize that none of the accumulation
equations, which we now use, correctly predict drug accumulation. Recently, Sahin
and Benet [13] defined a new parameter the ‘‘Operational multiple dosing half life’’
as equal to the dosing interval at steady state where the maximum concentration at
steady state is twice the maximum concentration found for the first dose and where
the fall off of plasma concentrations during a dosing interval at steady state is
reflective of this half life. We demonstrated for diazepam that the well accepted
concept that the terminal half life representing the great majority of the AUC will
govern accumulation, can be incorrect. Using oral diazepam, we demonstrated that
the operational multiple dosing half life is remarkably sensitive to the absorption
half life even when this absorption half life is much less than the terminal half life
and describe the relevance of this in designing extended release dosage forms [13].
Consider now telbivudine (Tyzeka) the Novartis drug for chronic hepatitis B.
Telbivudine has a distribution phase half-life of 2.0 h and a terminal elimination
half-life of 54 h [14]. Yet, at steady-state with once daily dosing, peak to trough
ratios are more than 10-fold. The package insert reads: Steady-state was achieved
after approx. 5–7 days of once daily oral dosing with *1.5-fold accumulation,
suggesting an effective half-life of *15 h [14]. From Eq. 7 the half-life for the
MRT in the body is 16.3 h and I calculate that the absorption half-life of telbivudine
is approximately 1.4 h. Using these parameters I calculated the steady state dosing
intervals that would yield two-fold increases for the maximum concentration at
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steady state (Cmax,ss) relative to the maximum concentration from a single dose
(Cmax,sd), the area under the curve during a dosing interval at steady state (AUCss) to
the area under the curve over the same time interval for a single dose (AUCsd) and at
steady state, the ratio of the maximum concentration (Cmax,ss) to the minimum
concentration (Cmin,ss), as given in Table 1. I calculate the ratio for a two-fold
increase because this yields a measure of the accumulation half-life for each of the
parameters. That is, if telbivudine was dosed every 7.1 h at steady state the
maximum to minimum concentration ratio would be 2.0 and if it was dosed every
14.2 h the ratio would approximate 4. Since the drug is given once daily, one can
understand now why peak to trough ratios at steady state are more than 10 fold since
we are dosing at intervals midway between 3 and 4 dosing interval half lives for this
parameter. Note in Table 1 that if the absorption half-life could be slowed to 7 h
then the peak to trough ratios would be approximately 4 at steady state for once
daily dosing, since the accumulation half life for this parameter is now 12.0 h.
Clearance again
Let’s return to clearance. With the recognition of the importance of drug
transporters during the last decade, how do we modify the clearance equations to
account for uptake and efflux transporters and particularly for transporter-enzyme
interplay? One generally unrecognized component of the clearance equations
developed by Professor Rowland is the assumption, that is really only explicitly
stated in the 1973 paper [3], that the partition ratio of free drug between the
circulating systemic fluids and the fluids within an eliminating organ is a constant
(usually equal to 1). Is this true when transporters are inhibited (or knocked out) or
induced?
Although knock-out animals have given us great insight into understanding the
importance of a variety of enzymatic and transporter disposition processes, they
cannot be trusted to provide quantitative pharmacokinetic characterization of these
processes. This is particularly true for evaluating enzyme-transporter interplay. In
general, investigators assume that knocking out one process does not affect another
in terms of quantitative clearance measurements. However, if this is not explicitly
tested, the assumptions are highly questionable, especially for transporter-enzyme
interactions. In essence, CLother must be shown to be constant.
Table 1 Telbivudine dosing
intervals yielding ratios of 2.0
for the respective parameters as
a function of absorption half-
life
Parameter Dosing interval (h)
t1/2,ka = 1.4 h t1/2,ka = 7.0 h
Cmax,ss/Cmax,sd = 2.0 4.9 12.4
AUCss/AUCsd = 2.0 5.4 13.6
Cmax,ss/Cmin,ss = 2.0 7.1 12.0
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Recently, Kusihara and Sugiyama [15] have developed a methodology to
evaluate hepatic clearance measures with the addition of transporters. They define:
CLint ¼ CLint;met þ PSint;bile ð8Þ
where PSint,bile is the intrinsic efflux clearance of unbound drug into the bile, while
CLint,met is the intrinsic metabolic clearance of unbound drug in the liver.
Now the intrinsic organ clearance (CLint,org) is:
CLint;org ¼ [PSinf= (PSeff þ CLintÞ  CLint ð9Þ
where PSinf and PSeff represent the intrinsic clearances for cellular uptake (influx)
and efflux into the systemic circulation, respectively.
At the boundary condition where CLint  PSeff, i.e., where the great majority of
drug taken up by the hepatocytes is metabolized or excreted into bile, then CLint,org
in Eq. 9 can be approximated by :
CLint;org ffi PSinf ð10Þ
Equation 10 appears to be consistent with the data for our atorvastatin isolated
perfused rat liver study [16], our in vivo rat studies [17] and our human study [10].
Watanabe et al. [18] concur with this conclusion where using multiple indicator
dilution perfusion studies, in vitro rat hepatocyte uptake studies and in vitro rat liver
microsome clearance measurements, they determine that the overall in vivo intrinsic
clearance measurements approximate the in vitro uptake clearance measurements.
They further predict in vivo human hepatic uptake clearance and suggest that these
values approximate overall human intrinsic clearance measurements for atorvastatin
and three other statins: pravastatin, pitavastatin and fluvastatin. These are excellent
ground breaking analyses, however, I recently suggested [9] that further tests should
be applied, incorporating efflux transporter and metabolism inhibition studies such
as those carried out in our laboratory and recently reviewed [9], as well as studies
where protein binding is changed. We suspect that other interactive processes may
be at work, which have not yet been adequately defined in terms of Eq. 8. For
example, the CLint,met portion of Eq. 8 is assumed to be independent of transport
processes in the derivation of Kusuhara and Sugiyama [15] and in all other
treatments of intrinsic metabolic clearance. As noted above, this is emphasized in
the derivation of Eq. 3 as proposed by Rowland et al. [3], where the partition
coefficient between unbound concentration in the measured systemic circulation and
that in the eliminating organ is assumed to be constant. However, inhibition,
induction or activation of transporters could potentially change this ratio so that in
essence what we now call intrinsic metabolic clearance is not intrinsic, but rather
varies with transporter changes. Our studies with atorvastatin in humans [10] not
only showed inhibition by rifampin of atorvastatin uptake into the liver but also
caused a change of the ratio of the atorvastatin lactone to the atorvastatin acid,
thereby changing the amount of substrate available to the enzymes in the liver since,
as we have shown earlier, metabolism by CYP3A4 of atorvastatin occurs via the
lactone, not the acid [19]. Thus, I suspect that there are still chapters in the clearance
book that need to be explicated and written.
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Conclusion
It is now 37 years since Professor Rowland introduced clearance concepts into
pharmacokinetics. The impact has been, by 1972 standards, unbelievable and
clearance has made pharmacokinetics an important underlying science in drug
development, selection of dosage regimens in patients and in the regulatory process.
As I have tried to point out here the development of clearance and its application is
ongoing and will continue to serve an important role in our scientific understanding
of drug disposition. It is only fitting that we recognize Professor Rowland’s seminal
and continuing contributions in this dedicatory issue.
Acknowledgments Supported in part by NIH Grants GM 75900 and GM 61390 and by an unrestricted
grant from Amgen, Inc.
Open Access This article is distributed under the terms of the Creative Commons Attribution
Noncommercial License which permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. von Bahr C, Alexanderson B, Azarnoff DL, Sjo¨qvist F, Orrenius S (1970) A comparative study of
drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol 9:99–105
2. Kru¨ger-Thiemer E, Diller W, Bu¨nger P (1965) Pharmacokinetic models regarding protein binding of
drugs. Antimicrob Agents Chemother 5:183–191
3. Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmaco-
kinet Biopharm 1:123–135
4. Wilkinson GR, Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance.
Clin Pharmacol Ther 18:377–390
5. Rowland M (1972) The influence of route of administration on drug availability. J Pharm Sci 16:
70–74
6. Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the volume of distribution
steady-state. J Pharm Sci 68:1071–1074
7. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver
disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–359
8. Sheiner LB, Rosenberg BG, Marathe VV (1988) Estimation of population characteristics of phar-
macokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445–479
9. Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay.
Mol Pharmaceut 6:1631–1643
10. Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B transporter inhibition on the
pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204
11. Zhang HX, Huang Y, Frassetto LZ, Benet LZ (2009) Elucidating rifampin’s inducing and inhibiting
effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the
differential effects of enzyme induction and transporter inhibition for a drug and its primary
metabolite. Clin Pharmacol Ther 85:78–85
12. Grover A, Benet LZ (2009) Effects of drug transporters on volume of distribution. AAPS J 11:
250–261
13. Sahin S, Benet LZ (2008) The operational multiple dosing half-life: a key to defining drug accu-
mulation in patients and to designing extended release dosage forms. Pharm Res 25:2869–2877
14. Telbuvidine Package Insert (2009) www.accessdata.fda.gov/drugsatfda_docs/label/2009/022011s0
02lbl. Accessed 31 Dec 2009
15. Kusuhara H, Sugiyama Y (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in
the liver and kidney. Drug Metab Pharmacokinet 24:37–52
538 J Pharmacokinet Pharmacodyn (2010) 37:529–539
123
16. Lau YY, Okochi H, Huang Y, Benet LZ (2006) Multiple transporters affect the disposition of
atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
J Pharmacol Exp Ther 316:762–771
17. Lau YY, Okochi H, Huang Y, Benet LZ (2006) Pharmacokinetics of atorvastatin and its hydroxy
metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass
effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos
34:1175–1181
18. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y (2010) Investigation
of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats
and humans. Drug Metab Dispos 38:215–222
19. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing K-F, Kollman PA, Benet LZ, Christians U
(2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-
CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369–1378
J Pharmacokinet Pharmacodyn (2010) 37:529–539 539
123
